Searched for
STRIDES PHARMA SHARE PRICE
Time for investors and traders to think alike? 7 Nifty Auto stocks with an upside potential of up to 19%There are sectors that have not quite followed the war script. Take the auto sector, for instance. A surge in oil prices is supposed to be ...- Quant Mid Cap Fund adds Adani Energy and 4 others, exits Paytm and 3 more stocks in MayQuant Mid Cap Fund, managed by Sandeep Tandon, has strategically adjusted its portfolio in May. The fund added Adani Energy and four other ...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- Ahead of Market: 10 things that will decide stock market action on TuesdayIndian equities rallied sharply as an interim US-Iran peace framework eased geopolitical concerns and pushed oil prices lower. Improved inf...
- Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports PlusStock Reports Plus, powered by Refinitiv, undertakes detailed company analysis for 4,000+ listed stocks. In addition to detailed company an...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 27%The US-Iran peace deal is finally about to happen. There is a high probability that global markets will see a relief rally, a part of which...
- Top Nifty50 stocks analysts suggest buying in this volatile weekStock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, ...
- Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports PlusStock Reports Plus, powered by Refinitiv, undertakes detailed company analysis for 4,000+ listed stocks. In addition to detailed company an...
- Quant Small Cap Fund raises stake in Adani Enterprises and 8 others, trims in Aurobindo Pharma and 4 moreQuant Small Cap Fund increased exposure to Adani Enterprises and eight other stocks in May while reducing holdings in Aurobindo Pharma and ...
- 'Not a great environment for Indian market': Harsha Upadhyaya on Iran-US tensions, IT outlook, pharma bet, and where to be cautiousGlobal challenges are impacting Indian stocks. West Asian tensions and rising US inflation create headwinds. Tech sector shifts also affect...
- Two Trades for Today: 2 pharma companies – a large-cap for a 5% rise, and a mid-cap stock for a gain of 7%Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
- LSEG slowly sheds 'AI risk' tag with drive to show growthLSEG shares tumbled nearly 13% in one day in February as worries about the threat posed by large language artificial intelligence models li...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Zydus Lifesciences, 2 other share buybacks closing today. Are you participating?Investors have a final opportunity to tender shares in buyback offers from Zydus Lifesciences, Dhanuka Agritech, and CyberTech Systems and ...
- Stocks in news: Emcure Pharma, Dixon Technologies, Ajanta Pharma, Godrej Properties, VedantaIndian markets experienced a volatile session, closing higher amidst mixed signals. Bulls are defending the 23,000 level in Nifty, but unce...
- Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
- Weekly Top Picks: These stocks scored 10 on 10 on Stock Reports PlusStock Reports Plus, powered by Refinitiv, undertakes detailed company analysis for 4,000+ listed stocks. In addition to detailed company an...
- Top Nifty50 stocks analysts suggest buying in this volatile weekStock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, ...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
Load More
